Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?

Executive Summary

New products continue to drive Lilly’s revenue growth and the company expects that to remain the case even if the final Phase III trial for Alzheimer’s candidate solanezumab fails later this year.

Advertisement

Related Content

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance
10 Things You Want To Know About Alzheimer's Drug Research
Lilly Executes Growth Strategy As New Products Drive Sales Gains
Lilly's Leap Tests Investors' Faith In Solanezumab
Lilly's Lung Cancer Drug Portrazza OK'd

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097542

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel